GGrantIndex
← Search

Structural Biology

$139,665P30FY2020CANIH

Albert Einstein College Of Medicine, Bronx NY

Investigators

Linked publications, trials & patents

Paper 39499645Paper 39392861Paper 39378878Paper 39332920Paper 39259591Paper 39207105Paper 39193906Paper 39127153Paper 39081315Paper 39028768Paper 39025270Paper 38902475Paper 38898085Paper 38896451Paper 38863869Paper 38778498Paper 38753503Paper 38717519Paper 38700353Paper 38699331Paper 38679747Paper 38657656Paper 38645169Paper 38643166Paper 38608634Paper 38597673Paper 38571760Paper 38565851Paper 38559037Paper 38477945Paper 38463959Paper 38458178Paper 38436133Paper 38405931Paper 38402617Paper 38400039Paper 38387080Paper 38352476Paper 38334805Trial NCT05016622Trial NCT04514484Trial NCT04401670Trial NCT03648983Trial NCT02774291Trial NCT02649569Trial NCT02578888Trial NCT02575872Trial NCT02527304Trial NCT02507076Trial NCT02382419Trial NCT02277561Trial NCT02112552Trial NCT02073968Trial NCT02038153Trial NCT02009436Trial NCT01958580Trial NCT01939210Trial NCT01899326Trial NCT01899261Trial NCT01897454Trial NCT01897441Trial NCT01857271Trial NCT01772420Trial NCT01697293Trial NCT01695941Trial NCT01605032Trial NCT01408160Trial NCT01367301Trial NCT01351909Trial NCT01319539Trial NCT01231906Trial NCT01145430Trial NCT01142401Trial NCT01061606Trial NCT01041027Trial NCT01001910Trial NCT00950365Trial NCT00470301Trial NCT00450944Trial NCT00437034Trial NCT00392353Trial NCT00324740Trial NCT00182767Trial NCT00179348Trial NCT00121251Trial NCT00096317Trial NCT00066638Trial NCT00057863Trial NCT00055692Trial NCT00030706Trial NCT00019474Trial NCT00004864Trial NCT00004863Trial NCT00003867Trial NCT00002461Patent 9671391Patent 7709613Patent 6821725Patent 6013468Patent 5876979

Abstract

PROJECT SUMMARY - STRUCTURAL BIOLOGY SHARED RESOURCE The Structural Biology Shared Resource (SBSR) provides comprehensive services and technologies for the generation of high resolution structural (X-ray, NMR, Cryo-EM) and proteomics analyses, and the technical expertise and intellectual infrastructure for interpretation and leveraging of these data to drive biochemical, cell biological and genetic experiments to discover novel biological processes and targets that lead to new therapeutic strategies. These traditional structural and proteomics methods are complemented by a wide range of computational, biochemical and biophysical approaches within Einstein and the AECC. The SBSR also provides considerable expertise in protein science, offering state-of-the-art automated capabilities in protein expression and purification, and receptor-ligand interaction analysis. Over the past funding period there have been significant technical, leadership, administrative and organizational enhancements. (i) The current AECC- supported Proteomics resource has been merged into the Structure Biology Shared Resource (SBSR) to capitalize on the scientific, technical and administrative synergies of this union, and an exceptional Proteomics co-director, Simone Sidoli from the U. of Penn, has been recruited. As part of this recruitment, the College has committed to the purchase of state-of-the-art instrumentation; (ii) A new senior co-director, David Cowburn, was recruited to lead the NMR component, providing enhanced capabilities in NMR and enhanced access to the New York Structural Biology Center with its expanded world-class cryo-electron microscopy infrastructure; (iii) There is now extensive access to the unique X-ray diffraction infrastructure at the newly established National Synchrotron Light Source-II (NSLS-II) at Brookhaven National Laboratory, as well as continued access to resources at Argonne National Laboratory; (iv) a new in-house X-ray data collection system was obtained through an NIH shared instrumentation grant; and v) with College support, high-throughput CRISPR screening and mAb discovery platforms have been implemented in association with the SBSR. Taken together, this unique set of technologies, and associated expert technical staff, supports a broad spectrum of studies on fundamental mechanisms underlying cancer biology, and enables the development of small molecules and biologics for novel treatment strategies that have resulted in considerable intellectual property and commercialization opportunities.

View original record on NIH RePORTER →